| A quantitative comparison of antibodies to programmed cell death 1 ligand 1 P Gaule, JW Smithy, M Toki, J Rehman, F Patell-Socha, D Cougot, ... JAMA oncology 3 (2), 256-259, 2017 | 202 | 2017 |
| Differential expression and significance of PD-L1, IDO-1, and B7-H4 in human lung cancer KA Schalper, D Carvajal-Hausdorf, J McLaughlin, M Altan, V Velcheti, ... Clinical Cancer Research 23 (2), 370-378, 2017 | 187 | 2017 |
| BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome SF Madden, C Clarke, P Gaule, ST Aherne, N O'Donovan, M Clynes, ... Breast cancer research 15, 1-14, 2013 | 153 | 2013 |
| B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes M Altan, V Pelekanou, KA Schalper, M Toki, P Gaule, K Syrigos, ... Clinical Cancer Research 23 (17), 5202-5209, 2017 | 113 | 2017 |
| PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus X Han, MD Vesely, W Yang, MF Sanmamed, T Badri, J Alawa, ... Science translational medicine 11 (522), eaax1159, 2019 | 87 | 2019 |
| PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple-negative breast cancer FS Ahmed, P Gaule, J McGuire, K Patel, K Blenman, L Pusztai, DL Rimm Clinical Cancer Research 26 (20), 5456-5461, 2020 | 72 | 2020 |
| Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray S Martinez-Morilla, J McGuire, P Gaule, L Moore, B Acs, D Cougot, ... Laboratory investigation 100 (1), 4-15, 2020 | 63 | 2020 |
| Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer M Moutafi, CJ Robbins, V Yaghoobi, AI Fernandez, S Martinez-Morilla, ... Laboratory Investigation 102 (10), 1101-1108, 2022 | 60 | 2022 |
| Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma JW Smithy, LM Moore, V Pelekanou, J Rehman, P Gaule, PF Wong, ... Journal for immunotherapy of cancer 5, 1-9, 2017 | 34 | 2017 |
| A new tool for technical standardization of the Ki67 immunohistochemical assay TN Aung, B Acs, J Warrell, Y Bai, P Gaule, S Martinez-Morilla, I Vathiotis, ... Modern Pathology 34 (7), 1261-1270, 2021 | 31 | 2021 |
| cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? PB Gaule, J Crown, N O’Donovan, MJ Duffy Expert Opinion on Therapeutic Targets 18 (9), 999-1009, 2014 | 31 | 2014 |
| Targeting pyruvate kinase M2 phosphorylation reverses aggressive cancer phenotypes M Apostolidi, IA Vathiotis, V Muthusamy, P Gaule, BM Gassaway, ... Cancer research 81 (16), 4346-4359, 2021 | 28 | 2021 |
| Dasatinib treatment increases sensitivity to c-met inhibition in triple-negative breast cancer cells P Gaule, N Mukherjee, B Corkery, AJ Eustace, K Gately, S Roche, ... Cancers 11 (4), 548, 2019 | 20 | 2019 |
| Spatially resolved and quantitative analysis of the immunological landscape in human meningiomas J Yeung, V Yaghoobi, TN Aung, MD Vesely, T Zhang, P Gaule, M Gunel, ... Journal of Neuropathology & Experimental Neurology 80 (2), 150-159, 2021 | 11 | 2021 |
| PD-L1 expression scoring: noninterchangeable, noninterpretable, neither, or both N Gavrielatou, S Shafi, P Gaule, DL Rimm JNCI: Journal of the National Cancer Institute 113 (12), 1613-1614, 2021 | 9 | 2021 |
| Bile acid distributions, sex-specificity, and prognosis in colorectal cancer Y Cai, X Shen, L Lu, H Yan, H Huang, P Gaule, E Muca, CM Theriot, ... Biology of Sex Differences 13 (1), 61, 2022 | 8 | 2022 |
| Targeting c-Met in triple negative breast cancer: Preclinical studies using the c-Met inhibitor, Cpd A L Breen, PB Gaule, A Canonici, N Walsh, DM Collins, M Cremona, ... Investigational New Drugs 38, 1365-1372, 2020 | 8 | 2020 |
| Multi-institutional study of pathologist reading of the programmed cell death ligand-1 combined positive score immunohistochemistry assay for gastric or gastroesophageal … AI Fernandez, CJ Robbins, P Gaule, D Agostini-Vulaj, RA Anders, ... Modern Pathology 36 (5), 100128, 2023 | 7 | 2023 |
| Multi-scale Pan-cancer integrative analyses identify the Stat3-VSIR axis as a key immunosuppressive mechanism in head and neck cancer R Katabathula, P Joseph, S Singh, S Zhao, B Kumar, P Gaule, Q Pan, ... Clinical Cancer Research 28 (5), 984-992, 2022 | 7 | 2022 |
| Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test AI Fernandez, P Gaule, DL Rimm Modern Pathology 36 (7), 100159, 2023 | 5 | 2023 |
